ASH Clinical News ACN_4.5_FULL_ISSUE_DIGITAL - Page 31

CLINICAL NEWS
died within 30 days of an MM diagnosis were excluded from the analysis of complications after diagnosis . Patients identified as :
• non-Hispanic white ( white ; 72 %)
• non-Hispanic black ( African- American ; 16.2 %)
• Hispanic ( 7.3 %)
• non-Hispanic Asian / Pacific Islander ( Asian ; 4.1 %)
• Native American ( including “ other ;” 0.3 %)
The researchers collected data on age and year of diagnosis , race , sex , disease complications , and
date and cause of death . They also assessed myeloma-defining events ( MDEs ) of interest : hypercalcemia , renal dysfunction , anemia , bone fracture , and dialysis .
The drug use analysis was limited to 2003 and later because bortezomib – the first proteasome inhibitor for MM – received U . S . Food and Drug Administration approval that year .
During the studied time period , more than half of patients ( 55 %) died because of MM .
The median age at diagnosis was 76 years ( range = 18-104 years ), and the median follow-up was 1.8 years ( range not reported ). Women were significantly older at diagnosis , compared with men ( median = 77 vs . 75 years ; ranges not provided ; p < 0.001 ).
KYMRIAH™ ( tisagenlecleucel ) suspension for intravenous infusion Initial U . S . Approval : 2017
BRIEF SUMMARY : Please see package insert for full prescribing information .
WARNING : CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL TOXICITIES
• Cytokine Release Syndrome ( CRS ), including fatal or life-threatening reactions , occurred in patients receiving KYMRIAH . Do not administer KYMRIAH to patients with active infection or inflammatory disorders . Treat severe or life-threatening CRS with tocilizumab [ see Dosage and Administration ( 2.2 , 2.3 ) in the full prescribing information , Warnings and Precautions ( 5.1 )].
• Neurological toxicities , which may be severe or life-threatening , can occur following treatment with KYMRIAH , including concurrently with CRS . Monitor for neurological events after treatment with KYMRIAH . Provide supportive care as needed [ see Warnings and Precautions ( 5.2 )].
• KYMRIAH is available only through a restricted program under a Risk Evaluation and Mitigation Strategy ( REMS ) called the KYMRIAH REMS [ see Warnings and Precautions ( 5.3 )].
1 INDICATIONS AND USAGE KYMRIAH is a CD19-directed genetically modified autologous T cell immuno - therapy indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia ( ALL ) that is refractory or in second or later relapse .
4 CONTRAINDICATIONS None .
5 WARNINGS AND PRECAUTIONS 5.1 Cytokine Release Syndrome Cytokine release syndrome ( CRS ), including fatal or life-threatening reactions , occurred following treatment with KYMRIAH . In Study 1 , CRS occurred in 79 % ( 54 / 68 ) of patients receiving KYMRIAH , including Grade 3 or 4 ( Penn grading system 1 ) CRS in 49 % ( 33 / 68 ) of patients . The median time to onset of CRS was 3 days ( range : 1-22 days ). Of the 54 patients with CRS , 27 ( 50 %) received tocilizumab ; 7 ( 13 %) patients received two doses of tocilizumab , 3 ( 6 %) patients received three doses of tocilizumab , and 14 ( 26 %) patients received addition of corticosteroids ( e . g ., methylprednisolone ). The median time to resolution of CRS was 8 days ( range : 1-36 days ).
Key manifestations of CRS include high fever , lower than normal blood pressure , difficulty breathing , and may be associated with hepatic , renal , and cardiac dysfunction , and coagulopathy .
Risk factors for severe CRS are high pre-infusion tumor burden ( greater than 50 % blasts in bone marrow ), uncontrolled or accelerating tumor burden following lymphodepleting chemotherapy , active infections , and / or inflam - matory processes .
Delay the infusion of KYMRIAH after lymphodepleting chemotherapy if the patient has unresolved serious adverse reactions from preceding chemotherapies ( including pulmonary toxicity , cardiac toxicity , or hypotension ), active uncontrolled infection , active graft versus host disease ( GVHD ), or worsening of leukemia burden [ see Dosage and Administration ( 2.2 ) in the full prescribing information ].
Ensure that tocilizumab is available on site prior to infusion of KYMRIAH . Monitor patients for signs or symptoms of CRS for at least 4 weeks after treatment with KYMRIAH . Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time [ see Patient Counseling Information ( 17 ) in the full prescribing information ]. At the first sign of CRS , immediately evaluate patient for hospitalization and institute treatment with supportive care , tocilizumab and / or cortico steroids as indicated [ see Dosage and Administration ( 2.3 ) in the full prescribing information ].
5.2 Neurological Toxicities Neurological toxicities , which may be severe or life-threatening can occur following treatment with KYMRIAH . The majority of neurological toxicities occurred within 8 weeks following KYMRIAH infusion . In Study 1 , neurological toxicities within 8 weeks after KYMRIAH infusion occurred in 65 % of patients , including Grade 3 or 4 neurological toxicities in 18 % of patients , and 75 % of events resolved within 12 days . The most common neurological toxicities were headache ( 37 %), encephalopathy ( 34 %), delirium ( 21 %), anxiety ( 13 %), and tremor ( 9 %). Other manifestations of neurological toxicities included disturbances in consciousness , disorientation , confusion , agitation , seizures , mutism and aphasia . Onset of neurological toxicity can be concurrent with CRS , following resolution of CRS or in the absence of CRS .
Monitor patients for neurological events and exclude other causes for neurological symptoms . Provide supportive care as needed for KYMRIAHassociated neurological events .
5.3 KYMRIAH REMS to Mitigate Cytokine Release Syndrome and Neurological Toxicities Because of the risk of CRS and neurological toxicities , KYMRIAH is available only through a restricted program under a Risk Evaluation and Mitigation Strategy ( REMS ) called the KYMRIAH REMS [ see Boxed Warning , Warnings and Precautions ( 5.1 , 5.2 )]. The required components of the KYMRIAH REMS are :
• Healthcare facilities that dispense and administer KYMRIAH must be enrolled and comply with the REMS requirements . Certified healthcare facilities must have on-site , immediate access to tocilizumab , and ensure that a minimum of two doses of tocilizumab are available for each patient for administration within 2 hours after KYMRIAH infusion , if needed for treatment of CRS .
• Certified healthcare facilities must ensure that healthcare providers who prescribe , dispense or administer KYMRIAH are trained about the management of CRS and neurological toxicities .
Further information is available at www . kymriah-rems . com or 1-844-4KYMRIAH .
5.4 Hypersensitivity Reactions Allergic reactions may occur with infusion of KYMRIAH . Serious hypersensitivity reactions , including anaphylaxis , may be due to the dimethyl sulfoxide ( DMSO ) or dextran 40 in KYMRIAH .
5.5 Serious Infections Serious infections , including life-threatening or fatal infections , occurred in patients after KYMRIAH infusion . In Study 1 , infections ( all Grades ) after KYMRIAH infusion occurred in 40 patients ( 59 %), including 24 patients ( 35 %) with Grade 3-4 infections and 2 patients ( 3 %) with fatal infections . Infections with an unknown pathogen occurred in 41 % of patients , viral infections in 26 %, bacterial infections in 19 %, and fungal infections in 13 %. Prior to KYMRIAH infusion , infection prophylaxis should follow local guidelines . Monitor patients for signs and symptoms of infection after treatment with KYMRIAH and treat appropriately [ see Dosage and Administration ( 2.3 ) in the full prescribing information ].
Febrile neutropenia ( Grade 3 or 4 ) was also observed in 37 % of patients after KYMRIAH infusion and may be concurrent with CRS . In the event of febrile neutropenia , evaluate for infection and manage with broad spectrum anti - biotics , fluids and other supportive care as medically indicated .
Viral Reactivation
Hepatitis B virus ( HBV ) reactivation , in some cases resulting in fulminant hepatitis , hepatic failure and death , can occur in patients treated with drugs directed against B cells . Hepatitis cases have been reported in patients who are hepatitis B surface antigen ( HBsAg ) positive , and also in patients who are HBsAg-negative but hepatitis B core antibody ( anti-HBc ) positive . HBV reactivation has occurred in patients who appear to have resolved hepatitis B infection ( i . e ., HBsAg-negative , anti-HBc-positive and hepatitis B surface antibody [ anti-HBs ] positive ).
HBV reactivation is defined as an abrupt increase in HBV replication manifesting as a rapid increase in serum HBV DNA level or detection of HBsAg in a person who was previously HBsAg-negative and anti-HBc-positive . Reactivation of HBV replication is often followed by hepatitis , i . e ., increase in trans - aminase levels . In severe cases , increase in bilirubin levels , liver failure , and death can occur .
Perform screening for HBV , HCV , and HIV in accordance with clinical guidelines before collection of cells for manufacturing .
5.6 Prolonged Cytopenias Patients may exhibit cytopenias for several weeks following lymphodepleting chemotherapy and KYMRIAH infusion Grade 3 and 4 cytopenias not resolved by Day 28 following KYMRIAH treatment included neutropenia ( 40 %), and thrombocytopenia ( 27 %) among 52 responding patients . At 56 days following KYMRIAH , 17 % and 12 % of responding patients had Grade 3 and 4 neutropenia or thrombo cytopenia respectively . Prolonged neutropenia has been associated with increased risk of infection . Myeloid growth factors , particularly GM-CSF , are not recommended during the first 3 weeks after KYMRIAH infusion or until CRS has resolved .
5.7 Hypogammaglobulinemia Hypogammaglobulinemia and agammaglobulinemia ( IgG ) can occur in patients with a complete remission ( CR ) after KYMRIAH infusion . In Study 1 , 43 % of patients had hypogammaglobulinemia . B-cell aplasia is an on-target effect of KYMRIAH and therefore a patient may experience hypogamma - globulinemia for as long as KYMRIAH persists [ see Clinical Pharmacology ( 12.3 ) in the full prescribing information ].
Monitor immunoglobulin levels after treatment with KYMRIAH and manage using infection precautions , antibiotic prophylaxis and immunoglobulin replacement standard guidelines .
The safety of immunization with live viral vaccines during or following KYMRIAH treatment has not been studied . Vaccination with live virus vaccines is not recommended for at least 2 weeks prior to the start of lymphodepleting
CLINICAL NEWS died within 30 days of an MM diagnosis were excluded from the analysis of complications after diagnosis. Patients identified as: • non-Hispanic white (white; 72%) • non-Hispanic black (African- American; 16.2%) • Hispanic (7.3%) • non-Hispanic Asian/Pacific Islander (Asian; 4.1%) • Native American (including “other;” 0.3%) The researchers collected data on B:7.75” age and year of diagnosis, race, T:7.5” sex, disease complications, and S:7” KYMRIAH™ (tisagenlecleucel) suspension for intravenous infusion Initial U.S. Approval: 2017 BRIEF SUMMARY: Please see package insert for full prescribing information. WARNING: CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL TOXICITIES • Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving KYMRIAH. Do not administer KYMRIAH to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab [see Dosage and Administration (2.2, 2.3) in the full prescribing information, Warnings and Precautions (5.1)]. • Neurological toxicities, which may be severe or life-threatening, can occur following treatment with KYMRIAH, including concurrently with CRS. Monitor for neurological events after treatment with KYMRIAH. Provide supportive care as needed [see Warnings and Precautions (5.2)]. • KYMRIAH is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the KYMRIAH REMS [see Warnings and Precautions (5.3)]. 1 INDICATIONS AND USAGE KYMRIAH is a CD19-directed genetically modified autologous T cell immuno - therapy indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. 4 CONTRAINDICATIONS None. Key manifestations of CRS include high fever, lower than normal blood pressure, difficulty breathing, and may be associated with hepatic, renal, and cardiac dysfunction, and coagulopathy. Risk factors for severe CRS are high pre-infusion tumor burden (greater than 50% blasts in bone marrow), uncontrolled or accelerating tumor burden following lymphodepleting chemotherapy, active infections, and/or inflam - matory processes. Delay the infusion of KYMRIAH after lymphodepleting chemotherapy if the patient has unresolved serious adverse reactions from preceding chemother- apies (including pulmonary toxicity, cardiac toxicity, or hypotension), active uncontrolled infection, active graft versus host disease (GVHD), or worsen- ing of leukemia burden [see Dosage and Administration (2.2) in the full prescribing information]. Ensure that tocilizumab is available on site prior to infusion of KYMRIAH. Monitor patients for signs or symptoms of CRS for at least 4 weeks after treatment with KYMRIAH. Counsel patients to seek immediate medical atten- tion should signs or symptoms of CRS occur at any time [see Patient Coun- seling Information (17) in the full prescribing information]. At the first sign of CRS, immediately evaluate patient for hospitalization and insti GWFRG&VBЦVBvF7W'FfR6&RF6ƗV"B"6'F67FW&G22F6FV@6VRF6vRBF֖7G&F"2FRgV&W67&&rf&FR"WW&v6F6FW0WW&v6F6FW2v6&R6WfW&R"ƖfRF&VFVr667W fvrG&VFVBvF$FR&GbWW&v6F6FW067W'&VBvFvVV2fvr$gW67GVGWW&vЦ6F6FW2vFvVV2gFW"$gW667W'&VBcRR`FVG26VFrw&FR2"BWW&v6F6FW2RbFVG2BsRRbWfVG2&W6fVBvF"F2FR7B6WW&v6F6FW2vW&RVF6R3rRV6WF3BRFVƗ&V#R熖WG2RBG&V"RFW"fW7FF2bWW&v6F6ЧFW26VFVBF7GW&&6W2666W6W72F6&VFF6gW6vFЧF6VW&W2WF6B66WBbWW&v6F6G6&P67W'&VBvF5%2fvr&W6WFb5%2"FR'6V6Rb5%2F"FVG2f"WW&v6WfVG2BW6VFRFW"6W6W2f WW&v67F2&fFR7W'FfR6&R2VVFVBf"$Ц766FVBWW&v6WfVG2GW&rFR7GVFVBFPW&B&RFbbFVG0SRRFVB&V6W6RbFRVFvRBFv60v2sbV'2&vR@V'2BFRVFfrWv2V'2&vRB&W'FVBvVvW&R6vf6FǒFW BFv626&VBvFVࢆVFsrg2sRV'3&vW0B&fFVCR2$$T2F֗FvFR7FR&VV6R7G&R@WW&v6F6FW0&V6W6RbFR&6b5%2BWW&v6F6FW2$2f&PǒF&Vv&W7G&7FVB&w&VFW"&6WfVFB֗FvF7G&FVw$T26VBFR$$T26VR&VBv&rv&w0B&V6WF2RR"FR&WV&VB6VG2bFR$$T2&S( "VF6&Rf6ƗFW2FBF7V6RBF֖7FW"$W7B&PV&VBB6ǒvFFR$T2&WV&VVG26W'FfVBVF6&Pf6ƗFW2W7BfR6FRVFFR66W72FF6ƗV"BV7W&PFB֖VbGvF6W2bF6ƗV"&Rf&Rf"V6FV@f"F֖7G&FvF"W'2gFW"$gW6bVVFVBf G&VFVBb5%2( "6W'FfVBVF6&Rf6ƗFW2W7BV7W&RFBVF6&R&fFW'2v&W67&&RF7V6R"F֖7FW"$&RG&VB&WBFRvRЦVBb5%2BWW&v6F6FW2gW'FW"f&F2f&RBwwr淖&&V26 ӃCBD$RBW'6V6FfG&V7F0W&v2&V7F267W"vFgW6b$6W&W2W'6V6ЧFfG&V7F26VFr2&RGVRFFRFWF7VfFPD4"FWG&C$RR6W&W2fV7F06W&W2fV7F26VFrƖfRF&VFVr"fFfV7F267W'&VBFVG2gFW"$gW67GVGfV7F2w&FW2gFW $gW667W'&VBCFVG2SR6VFr#BFVG03RRvFw&FR2BfV7F2B"FVG22RvFfFfV7F2खfV7F2vFVvFvV67W'&VBCRbFVG2f&fV7F2#bR&7FW&fV7F2RBgVvfV7F22R&"F$gW6fV7F&26VBfr6wVFRЦƖW2F"FVG2f"6v2B7F2bfV7FgFW"G&VFV@vF$BG&VB&&FVǒ6VRF6vRBF֖7G&F"2FRgV&W67&&rf&FfV'&RWWG&Vw&FR2"Bv26'6W'fVB3rRbFVG2gFW $gW6B&R67W'&VBvF5%2FRWfVBbfV'&PWWG&VWfVFRf"fV7FBvRvF'&B7V7G'VFЦ&F72fVG2BFW"7W'FfR6&R2VF6ǒF6FVBf&&V7FfFआWFF2"f'W2%b&V7FfF6R66W2&W7VFrgV֖@WFF2WF2fW&RBFVF667W"FVG2G&VFVBvFG'Vw0F&V7FVBv7B"6V2WFF266W2fR&VV&W'FVBFVG2v&RWFF2"7W&f6RFvV'4r6FfRB6FVG2v&P'4rVvFfR'WBWFF2"6&RF&GFԄ&26FfR%b&V7FЧfF267W'&VBFVG2vV"FfR&W6fVBWFF2 fV7FR'4rVvFfRFԄ&26FfRBWFF2"7W&f6PF&GFԄ'56FfRऄ%b&V7FfF2FVfVB2''WB7&V6R%b&WƖ6FЦfW7Fr2&B7&V6R6W'V%bDWfV"FWFV7Fb'4rW'6vv2&WfW6ǒ'4rVvFfRBFԄ&26FfR&V7FЧfFb%b&WƖ6F2gFVfvVB'WFF2R7&V6RG&2Ц֖6RWfV26WfW&R66W27&V6R&Ɨ'V&WfV2ƗfW"fW&R@FVF667W"W&f&67&VVrf"%b5bBb66&F6RvF6Ɩ6wVFRЦƖW2&Vf&R6V7Fb6V2f"Vf7GW&rRb&vVB7FV0FVG2W&B7FV2f"6WfW&vVV2fvrǖFWWFp6VFW&B$gW6w&FR2BB7FV2B&W6fV@'F#fvr$G&VFVB6VFVBWWG&VCR@F&&7FV#rRrS"&W7FrFVG2BSbF2frЦr$rRB"Rb&W7FrFVG2Bw&FR2BBWRЧG&V"F&&7FV&W7V7FfVǒ&vVBWWG&V2&VV766FVBvF7&V6VB&6bfV7FזVBw&wFf7F'2'F7RЦ&ǒt54b&RB&V6VFVBGW&rFRf'7B2vVV2gFW"$gW6"VF5%22&W6fVBRrvv'VƖV֖vv'VƖV֖Bvv'VƖV֖tr667W"FVG2vF6WFR&V֗765"gFW"$gW67GVGC2RbFVG2Bvv'VƖV֖"6V62F&vW@VffV7Bb$BFW&Vf&RFVBWW&V6RvЦv'VƖV֖f"2r2$W'67G26VR6Ɩ6&6w"2FRgV&W67&&rf&FF"Vv'VƖWfV2gFW"G&VFVBvF$BvPW6rfV7F&V6WF2F&F2&2BVv'VƖ&W6VVB7FF&BwVF